-
Featured
Mortality in COVID-19 Does Not Appear to Be Driven by Liver Failure
Massachusetts General Hospital researchers report that elevated liver function tests are common in COVID-19, but severe liver injury is rare, and no case of liver failure or dysfunction leading to death has been attributed directly to COVID-19.
-
Featured
Patients with Decompensated Cirrhosis Need Earlier End-of-Life Planning
Regardless of transplant candidacy, patients with decompensated cirrhosis spend a substantial portion of their last 90 days of life in the hospital, are likely to receive intensive interventions at the end of life and tend to be referred late, if at all, to palliative or hospice care.
-
Featured
Early Transplantation for Alcohol-associated Hepatitis Improves Survival
According to a mathematical model, offering liver transplantation with no minimum period of sobriety before surgery (i.e., early liver transplantation) for severe alcohol-associated hepatitis provides a fourfold increase in life expectancy compared with requiring a six-month period of sobriety before listing. having characteristics similar to patients in ACCELERATE-AH trial.
-
Futibatinib Efficacious for FGFR2 Fusion/Rearrangement Positive Intrahepatic Cholangiocarcinoma in Phase 2 Multinational Trial
Lipika Goyal, MD, MPhil and colleagues have reported futibatinib efficacy and safety data from the multinational phase 2 FOENIX-CCA2 trial, which led to accelerated FDA approval of the drug for patients who have advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions or rearrangements.
-
Novel AI Model Predicts Risk of Hepatic Toxicity After Radiation Therapy for HCC
Mass General Cancer Center researchers have created a new machine learning approach to predict an individual patient's risk of hepatic toxicity after conformal radiation therapy for hepatocellular carcinoma: training convolutional neural networks on differential dose-volume histograms as well as clinical factors.
-
Medical Grand Rounds: Updates in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma
In a Medical Grand Rounds presentation, Kathleen Corey, MD, MPH, MMSc, and Tracey Simon, MD, MPH, of the Division of Gastroenterology at Massachusetts General Hospital, presented on the assessment of non-alcoholic fatty liver disease and the prevention of hepatocellular carcinoma.
Liver Contributors
-
Emily D. Bethea, MD
Associate Clinical Director of Liver Transplantation, Massachusetts General Hospital
-
Jagpreet Chhatwal, PhD
Associate Director, Institute for Technology Assessment, Assistant Professor, Harvard Medical School
Recent Article
County-level COVID-19 Data Confirms Effectiveness of Workplace Closure
-
Kathleen E. Corey, MD, MPH, MMSc
Director, Fatty Liver Clinic, Mass General Gastrointestinal Unit, Associate Professor of Medicine, Harvard Medical School
Recent Article
Medical Grand Rounds: Updates in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma
-
Raymond T. Chung, MD
Vice Chief, Division of Gastroenterology, Director, Hepatology and Liver Center, Massachusetts General Hospital
Recent Article
Monitoring Novel HBV Markers Worthwhile in HBeAg-positive Patients Coinfected With HIV
-
Russell P. Goodman, MD, DPhil
Hepatologist, Division of Gastroenterology, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Imbalance of Electrons in the Liver May Be A Risk Factor for Many Common Diseases
Digestive Healthcare at Mass General
The Massachusetts General Hospital Digestive Healthcare Center is a collaborative practice of gastroenterologists, endoscopists, surgeons, radiologists, pathologists, hepatologists, oncologists and radiation oncologists dedicated to the prevention, diagnosis, treatment and management of digestive diseases.